PMID- 35988035
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20230413
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Print)
IS  - 0307-6938 (Linking)
VI  - 47
IP  - 12
DP  - 2022 Dec
TI  - Retinoid-induced skeletal hyperostosis in disorders of keratinization.
PG  - 2273-2276
LID - 10.1111/ced.15382 [doi]
AB  - For disorders of keratinization, topical treatment alone may be ineffective, and 
      systemic retinoid therapy may be indicated. Treatment with systemic retinoids 
      (acitretin, isotretinoin and alitretinoin) has been shown to be effective in 
      reducing disease severity; however, potentially rare adverse effects (AEs) may 
      occur, including hyperostotic skeletal changes. The true prevalence of this AE in 
      adult patients administered life-long therapy is unknown. We identified 3 of 127 
      (2.4%) patients (with ichthyosis or Darier disease) who had been prescribed 
      isotretinoin with or without acitretin, and who developed radiological signs and 
      clinical symptoms of hyperostosis and ligamentous ossification. This clinical 
      review highlights the significance of retinoid-induced skeletal hyperostosis in 
      patients prescribed long-term, high-dose retinoid therapy for disorders of 
      keratinization. Patients commencing systemic retinoid therapy, particularly women 
      of childbearing age, should be counselled about this important and potentially 
      serious AE, especially if long-term treatment is indicated.
CI  - (c) 2022 The Authors. Clinical and Experimental Dermatology published by John Wiley 
      & Sons Ltd on behalf of British Association of Dermatologists.
FAU - Doolan, Brent J
AU  - Doolan BJ
AUID- ORCID: 0000-0002-9497-0504
AD  - St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, 
      London, UK.
AD  - St John's Institute of Dermatology, School of Basic and Medical Biosciences, 
      King's College London, UK.
FAU - Paolino, Alexandra
AU  - Paolino A
AD  - St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, 
      London, UK.
FAU - Greenblatt, Danielle T
AU  - Greenblatt DT
AUID- ORCID: 0000-0002-7505-3567
AD  - St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, 
      London, UK.
AD  - St John's Institute of Dermatology, School of Basic and Medical Biosciences, 
      King's College London, UK.
FAU - Mellerio, Jemima E
AU  - Mellerio JE
AUID- ORCID: 0000-0002-2670-8117
AD  - St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, 
      London, UK.
AD  - St John's Institute of Dermatology, School of Basic and Medical Biosciences, 
      King's College London, UK.
LA  - eng
PT  - Journal Article
DEP - 20220927
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - LCH760E9T7 (Acitretin)
RN  - EH28UP18IF (Isotretinoin)
RN  - 1UA8E65KDZ (Alitretinoin)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Female
MH  - Acitretin/adverse effects
MH  - Isotretinoin/therapeutic use
MH  - Alitretinoin/adverse effects
MH  - *Hyperostosis/chemically induced/drug therapy
MH  - *Ichthyosis/drug therapy
PMC - PMC10087317
COIS- The authors declare that they have no conflict of interest.
EDAT- 2022/08/22 06:00
MHDA- 2022/11/30 06:00
PMCR- 2023/04/11
CRDT- 2022/08/21 05:22
PHST- 2022/08/19 00:00 [accepted]
PHST- 2022/08/22 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/08/21 05:22 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - CED15382 [pii]
AID - 10.1111/ced.15382 [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2022 Dec;47(12):2273-2276. doi: 10.1111/ced.15382. Epub 2022 
      Sep 27.